Neowise Biotechnology completes RMB 200M+ Series B financing to accelerate clinical development of TCR-T cell therapies for solid tumors

Recently, Neowise Biotechnology ("Neowise"), an innovative biotech company dedicated to developing TCR-T immunocellular therapies for solid tumors, recently announced the completion of a Series B financing round exceeding 200 million. This round was jointly led by Apricot Capital and a prominent industry-focused fund, with participation from Delian Capital, Oriza Holdings, and the Suzhou Angel FOF. Existing shareholders Orange Land Capital and GEM continued their strong support. HaoYue Capital acted as the exclusive financial advisor for this financing round.

Founded in 2020 and headquartered in Suzhou, Neowise is an innovative enterprise focused on developing TCR-T immunocellular therapeutic drugs for solid tumors. Neowise has independently developed a high-throughput, high-sensitivity platform for discovering target antigen-natural TCR pairings. By iteratively integrating computational analysis with experimental validation feedback, this platform efficiently screens for natural, high-affinity TCR sequences that specifically recognize tumor antigens. Leveraging this platform, Neowise has established the globally leading, experimentally validated tumor target antigen-natural TCR pairing database, CAST®. Neowise currently has multiple drug candidates advancing through the clinical trial stage, where encouraging efficacy and favorable safety profiles have been observed in trials targeting various solid tumors.

Among its pipeline, NW-101C is a TCR-T cell therapy candidate drug independently developed by Neowise, targeting PRAME. It is the first product in China directed against this target to enter the clinical stage and has demonstrated promising efficacy in multiple advanced, late-line solid tumors. Currently undergoing Phase I registration clinical studies, its potential indications include ovarian cancer, malignant melanoma, esophageal squamous cell carcinoma, lung squamous cell carcinoma, soft tissue sarcoma, and triple-negative breast cancer.

NW-301V is another TCR-T cell therapy candidate drug independently developed by Neowise, targeting the KRAS G12V mutation. Preliminary clinical research results for NW-301V were presented as a proffered paper presentation at the 2025 ESMO Annual Meeting, marking the first global systematic disclosure of clinical data for a TCR-T drug targeting this specific mutation. Among 14 evaluable patients with advanced colorectal cancer, pancreatic cancer, and other malignancies enrolled by July 2025, NW-301V demonstrated a favorable safety and efficacy profile. In terms of safety, no dose-limiting toxicities or severe adverse reactions were reported. Regarding efficacy, among the 10 subjects treated in the medium- and high-dose cohorts, the objective response rate (ORR) reached 50%, and the disease control rate (DCR) reached 100%.

The proceeds from this Series B financing will be primarily allocated to advancing the clinical research of Neowise's core drug candidates and progressing several preclinical pipelines. This funding will accelerate Neowise's journey towards clinical development, commercialization, and internationalization of its innovative therapies. Supported by this new capital, Neowise is poised to further expand its portfolio, with the ultimate goal of bringing benefits to a broad patient population as soon as possible.